LB Pharmaceuticals names seasoned CNS CMO as LB-102 pipeline enters late-stage execution

LB Pharmaceuticals is a late-stage neuromedicine company pushing its lead candidate LB-102 through a pivotal Phase 3 schizophrenia trial and a Phase 2 bipolar-depression trial, while expanding toward additional psychiatric indications. The appointment strengthens the execution bench. Susan Kozauer brings recent senior clinical-development experience at Centessa and earlier experience at Intra-Cellular Therapies, which is directly relevant as LB-102 moves through multiple late-stage programs. 〔0〕

This is an operational upgrade, not a pipeline inflection. The filing adds no efficacy, safety, regulatory, enrollment, or timing change; it mainly puts an experienced psychiatric-development leader in place to manage a program whose value still depends on future trial execution. 〔1〕

The package is meaningful but not destabilizing for a clinical-stage company. Kozauer receives a $515,000 base salary, a 40% target bonus, a $150,000 sign-on payment, and an option for 200,000 shares that vests over four years. 〔2〕 The equity award aligns her with longer-term development milestones, while the severance and change-of-control protections are standard executive-retention provisions rather than evidence of a strategic transaction.

Bottom line: This is a credible management addition at an important execution point, but it does not change the clinical risk or the timing of LB-102’s value drivers. The business story improves modestly; the next meaningful proof remains trial progress, not the hiring itself.